OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) – Opportunity Analysis and Forecasts to 2017

Publisher Name :
Date: 30-Sep-2013
No. of pages: 128

GlobalData has released its new Opportunity Analyzer report, “Nonalcoholic Steatohepatitis (NASH) – Opportunity Analysis and Forecasts to 2017”. The NASH market is currently deserted and awaits its first NASH-specific therapy. With novel mechanism of action awaiting approval such as: Genfit’s PPAR agonist, GFT505 and Intercept Pharmaceuticals/Dainippon Sumitomo Pharma’s FXR agonist, Obeticholic Acid. These compounds will race to be the first approved therapy thus claiming first in class.

Scope

  • Overview of NASH, including epidemiology, etiology, symptoms, diagnosis, pathology and disease management.
  • Analysis of the current and future market competition in the global NASH therapeutics market.
  • Pipeline analysis: comprehensive data split across Phase II/IIb, emerging trends and mechanisms of action under development, including: oral Proliferator Activated Receptor alpha, delta (PPARa,d) agonist, oral Farnesoid X Receptor (FXR) agonist, subcutaneous Lysyl Oxidase-Like 2 (LOXL2) inhibitor and subcutaneous Glucagon-like Peptide-1 (GLP-1) agonist.
  • Annualized NASH therapeutics market forecast, annual cost of therapy and treatment usage pattern data from 2012-2017.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
  • Key topics covered include strategic clinical and commercial benchmarking assessment of the pipeline and standard of care, market outlook, R&D strategies, and unmet needs for the NASH therapeutics market.

Reasons To Buy

Develop business strategies and perform superior market quantification analysis by:

  • Understanding the trends shaping and driving the global NASH Therapeutics market.
  • Understanding treatment preferences of physicians in disease state and across treatment flow.
  • Accessing market sizing, forecasts and quantified growth opportunities in the global NASH Therapeutics market till 2017.
  • Quantifying patient population in the global NASH Therapeutics market to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
  • Performing benchmarking analysis and growth opportunities against currently marketed products.
  • Identifying market entry points based on safety, efficacy, and pricing parameters.
  • Assessing competitiveness of products in market by understanding the strength and weakness of current competition.
  • Develop and design your in-licensing and out-licensing strategies by
  • Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.
  • Assessing strength of pipeline based on first in class and lifecycle management of products.
  • Analyze the potential impact of novel oral therapies such as Genfit’s GFT505 on the NASH treatment paradigm.
  • Track drug sales in the global NASH Therapeutics market from 2012 to 2017.
  • Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
  • What’s the next big thing in the global NASH Therapeutics market landscape? Identify, understand, and capitalize.

OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) – Opportunity Analysis and Forecasts to 2017

Table of Contents

1 Table of Contents 7
1.1 List of Tables 11
1.2 List of Figures 12

2 Introduction 13
2.1 Catalyst 13

3 Disease Overview 14
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 15
3.2 Symptoms 19

4 Epidemiology 21
4.1 Disease Background 21
4.2 Risk Factors and Comorbidities 22
4.2.1 Increased age is associated with a worsened disease progression, prognosis, and mortality 22
4.2.2 Being a male is an independent risk factor in morbidly obese NASH cases 23
4.2.3 Metabolic conditions, such as type 2 diabetes, considerably increase the risk of NASH 25
4.3 Global and Historical Trends 26
4.3.1 US 28
4.3.2 5EU 29
4.4 Forecast Methodology 31
4.4.1 Sources Used 33
4.4.2 Forecast Assumptions and Methods 35
4.4.3 Sources Not Used 38
4.5 Epidemiology Forecast of Nonalcoholic Steatohepatitis (2012-2022) 39
4.5.1 Total Prevalent Cases of Nonalcoholic Steatohepatitis 39
4.5.2 Age-Specific Prevalent Cases of Nonalcoholic Steatohepatitis 41
4.5.3 Sex-Specific Prevalent Cases of Nonalcoholic Steatohepatitis 44
4.5.4 Age-Standardized Prevalence of Nonalcoholic Steatohepatitis 45
4.6 Discussion 46
4.6.1 Conclusions on Epidemiological Trends 46
4.6.2 Limitations of the Analysis 47
4.6.3 Strengths of the Analysis 48

5 Current Treatment Options 49
5.1 Overview 49
5.2 Product Profiles - Major Off-Label Brands 52
5.2.1 Vitamin E (numerous generics) 52
5.2.2 Pioglitazone (Actos) 56

6 Unmet Needs Assessment and Opportunity Analysis 61
6.1 Overview 61
6.2 Unmet Needs Analysis 63
6.2.1 Lack of Approved Therapies 63
6.2.2 Identification of Biomarkers for Early Diagnosis and Endpoints 64
6.2.3 Physician Awareness Due to Understanding of Pathophysiology 65
6.3 Opportunity Analysis 65
6.3.1 Therapies with Targeted MOA to NASH 65
6.3.2 Better Models to Understand Drug Efficacy 65
6.3.3 Future Tool to Measure Fibrosis in NASH Patients 66

7 R&D Strategies 67
7.1 Overview 67
7.1.1 Understanding Multiple Factors of NASH 67
7.1.2 Potential for a Personalized Approach 68
7.2 Clinical Trial Design 69
7.2.1 Differences in Diagnosis, Monitoring, and Sensitive Imaging Techniques Are Needed 70
7.2.2 Patient Recruitment Issues 70
7.2.3 Appropriate Endpoints 71
7.2.4 Clinical Regulatory Guidelines 72

8 Pipeline Assessment 74
8.1 Overview 74
8.2 Promising Drugs in Clinical Development 75
8.2.1 GFT505 76
8.2.2 Obeticholic Acid (INT-747) 80
8.2.3 Simtuzumab (Formerly GS-6624) 84
8.2.4 Liraglutide (Victoza) 88
8.3 Innovative Early-Stage Approaches 92
8.3.1 Targeting Cytokines 93

9 Pipeline Valuation Analysis 95
9.1 Clinical Benchmark of Key Pipeline Drugs 95
9.2 Commercial Benchmark of Key Pipeline Drugs 98
9.3 Competitive Assessment 100
9.4 Top-Line Five-Year Forecast 101
9.4.1 US 105
9.4.2 5EU 106

10 Appendix 108
10.1 Bibliography 108
10.2 Abbreviations 116
10.3 Methodology 119
10.4 Forecasting Methodology 119
10.4.1 Diagnosed NASH Patients 119
10.4.2 Percent Drug-Treated Patients 120
10.4.3 Drugs Included in Each Therapeutic Class 120
10.4.4 Launch Dates 121
10.4.5 General Pricing Assumptions 121
10.4.6 Individual Off-Label Drug Assumptions 122
10.4.7 Pricing of Pipeline Agents 122
10.5 Physicians and Specialists Included in this Study 123
10.6 About the Authors 124
10.6.1 Author 124
10.6.2 Epidemiologist 125
10.6.3 Global Head of Healthcare 126
10.7 About GlobalData 127
10.8 Disclaimer 127

List of Tables

Table 1: Symptoms of NASH 19
Table 2: Risk Factors and Comorbidities for NASH 22
Table 3: Reported Prevalence of NASH in the US and 5EU 27
Table 4: Reported Prevalence of NAFLD in the US and 5EU 27
Table 5: 6MM, Sources of Prevalence Data Used in the NASH Epidemiological Forecast 32
Table 6: 6MM, Prevalent Cases of NASH, Ages ≥ 20 Years, Men and Women, N, Selected Years, 2012-2022 40
Table 7: 6MM, Prevalent Cases of NASH, By Age*, Men and Women, N (Row %), 2012 42
Table 8: 6MM, Prevalent Cases of NASH, Ages ≥ 20 Years, By Sex, N (Row %), 2012 44
Table 9: Off-Label Treatments for NASH 51
Table 10: Product Profile - Vitamin E 53
Table 11: Vitamin E SWOT Analysis in NASH, 2013 55
Table 12: Product Profile - Pioglitazone 57
Table 13: Pioglitazone SWOT Analysis in NASH, 2013 60
Table 14: Overall Unmet Needs in NASH - Current Level of Attainment 62
Table 15: Current Clinical Trial Design of Key Pipeline Drugs for NASH, 2013 73
Table 16: NASH - Mid-Late-Stage Pipeline, 2013 75
Table 17: Product Profile - GFT505 77
Table 18: GFT505 SWOT Analysis, 2013 79
Table 19: Product Profile - Obeticholic Acid (INT-747) 81
Table 20: Obeticholic Acid (INT-747) SWOT Analysis, 2013 83
Table 21: Product Profile - Simtuzumab 85
Table 22: Simtuzumab SWOT Analysis, 2013 87
Table 23: Product Profile - Liraglutide 89
Table 24: Liraglutide Safety Profile from the LEAD Program 90
Table 25: Liraglutide SWOT Analysis, 2013 91
Table 26: Early-Stage Pipeline Products in NASH, 2013 93
Table 27: Clinical Benchmark of Key Pipeline Drugs for NASH, 2013 97
Table 28: Commercial Benchmark of Key Pipeline Drugs for NASH, 2013 99
Table 29: Top-Line Sales Forecasts ($m) for NASH, 2012-2017 102
Table 30: Key Events Impacting Sales for NASH, 2017 103
Table 31: NASH Market: US and 5EU - Drivers and Barriers, 2012-2017 104
Table 32: Key Launch Dates 121

List of Figures

Figure 1: Two-Hit and Multiple-Hits Theories in NASH 16
Figure 2: Distinct-Hit Pathogenesis in NASH 18
Figure 3: Stages of Liver Disease 20
Figure 4: 5EU, Prevalence of NAFLD and Obesity, Ages ≥ 20 Years, Men and Women, % 30
Figure 5: 6MM, Prevalent Cases of NASH, Ages ≥ 20 Years, Men and Women, N, Selected Years, 2012-2022 40
Figure 6: 6MM, Prevalent Cases of NASH, By Age*, Men and Women, N, 2012 43
Figure 7: 6MM, Prevalent Cases of NASH, Ages ≥ 20 Years, By Sex, N, 2012 45
Figure 8: Liver Biopsy to Confirm NASH 50
Figure 9: Competitive Assessment of Mid-Stage Pipeline Agents in NASH, 2012-2017 76
Figure 10: Competitive Assessment of Mid-Stage Pipeline Agents in NASH, 2012-2017 100
Figure 11: Global Sales for NASH by Region, 2012-2017 103

  • Global Dental Implants Market Driven by Demand in Cosmetic Dentistry
    The global market for dental implants has been witnessing steady growth in the last couple of years due to increased demand for cosmetic dentistry and rise in incidences of dental disorders. People’s awareness about aesthetic dentistry procedures has increased in recent years, which is also fueling the growth of the dental implant market. With economic [...]
  • Air Traffic Management and Control Market Driven by Technological Advancement
    The global market for air traffic management and control has grown steadily in the last couple of years with increase in air traffic volume and congestion. Air Traffic Control (ATC) consists of an elaborate system of ground stations, radar arrays and professional air traffic controllers. With increase in air travel for business and leisure, as [...]
  • Global Stem Cell Therapy Industry Witnesses Steady Growth
    Stem cell research which is one of the most contemporary areas of biology has developed rapidly in the last couple of years. Increased funding in stem cell research by both government and private organizations is one of the main drivers in the stem cell therapy industry. Stem cells are used in various medical therapies such [...]
  • Global Lubricant Market Driven by Increased Demand in Automotive Industry
    With growth in the automobile industry, the demand for lubricants has also increased. The robust growth in manufacturing with increase in industrial production, particularly in countries such as China and India are also fueling the demand for lubricants. In 2013, the global market for lubricants had reached a value of 123.64 billion USD. By 2020, [...]
  • Global Cybersecurity Market Driven by Increase in Cyber Attacks
    In recent years, the global market for cybersecurity has grown steadily, with the rapid adoption of cloud-based services. As more and more corporate and government organizations are realizing the importance of protecting data and intellectual property, the market for cybersecurity is going to expand. In 2014, the global market for cybersecurity was valued at 95.60 [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Empty Capsules Market by Product (Hard gelatin, Non-gelatin capsules), Raw Material (Pig meat, Bovine, HPMC), Therapeutic Application (Antibiotics, Vitamins) & by End User (Pharmaceutical, Health Supplements) – Global Forecast to 2019
    Published: 26-Nov-2014        Price: US $4650 Onwards        Pages: 210
    Over the last decade, the empty capsules market is experiencing growth primarily due to the rising aging population and technological innovations in the empty capsules market. The fast-growing pharmaceutical and nutraceutical industries are catalyzing the growth of the empty capsules market. In this report, the global empty capsules market is segmented by products, source of raw materials, therapeutic applications, and end users. The empty capsules products market is segmented into hard gelat......
  • 2014 Market Research Report on Global Insulin Industry
    Published: 26-Nov-2014        Price: US $2200 Onwards        Pages: 139
    This is a professional and depth research report on Global Insulin industry. For overview analysis, the report introduces Insulin basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis, etc. For international and China market analysis, the report analyzes Insulin markets in China and other countries or regions (such as US, Europe, Japan, etc) by presenting research on global products of different ......
  • Argentina Pharmaceuticals and Healthcare Report Q1 2015
    Published: 26-Nov-2014        Price: US $1295 Onwards        Pages: 135
    BMI View: We expect increasing competitive pressure in the Argentine pharmaceutical sector as South- South relations continue to develop. This is illustrated by the Argentine government recent authorization for Indian pharmaceutical firms to export finished formulations to Argentina. Argentina's debt default poses downside risk to economic activity in the next quarters, while we expect inflation and drug pricing controls to continue hampering the pharmaceutical market potential. The challeng......
  • Botswana Pharmaceuticals and Healthcare Report Q1 2015
    Published: 26-Nov-2014        Price: US $1295 Onwards        Pages: 63
    BMI View: Our outlook for the pharmaceutical and healthcare markets of Botswana is reasonably positive due to the government's increasing commitment to improve the country's healthcare sector. The country's import reliance for pharmaceuticals, coupled with the forecast depreciation of the Botswana pula will be seen as a negative for the local industry as imports will become increasingly expensive. Headline Expenditure Projections ? Pharmaceuticals: BWP1.66bn (USD198mn) in 2013 to BWP1.85bn ......
  • Cameroon Pharmaceuticals and Healthcare Report Q1 2015
    Published: 26-Nov-2014        Price: US $1295 Onwards        Pages: 56
    BMI View: Against a backdrop of sustained economic growth, Cameroon's pharmaceuticals and healthcare market will sustain an expansive trajectory over the medium-to-long term. Although from a low per-capita spending level, population growth and rising incomes will drive drug consumption in the foreseeable future. A number of public and private investment projects across the healthcare system will contribute to overall sector growth, as illustrated by recent investment projects by Swiss entrep......
  • Mozambique Pharmaceuticals and Healthcare Report Q1 2015
    Published: 26-Nov-2014        Price: US $1295 Onwards        Pages: 52
    BMI View: Mozambique has a fast-growing economy thanks to its natural resources and agricultural industry. The Mozambican government continues to show its commitment towards the development of healthcare infrastructure by tackling the country's shortages of health professionals and clinic with the aid of foreign investors. However, barriers to investment remain, including high levels of corruption and lowlevel political instability, working against market growth. Headline Expenditure Foreca......
  • Singapore Pharmaceuticals and Healthcare Report Q1 2015
    Published: 26-Nov-2014        Price: US $1295 Onwards        Pages: 133
    BMI View: Driven by a rapidly ageing population and growing government health expenditure, Singapore's pharmaceutical sales will continue its steady growth over the next decade. This growth is only constrained by its small population. The country's high levels of education, strong patent protection and good infrastructure also makes it a highly competitive location for international pharmaceutical companies to establish research and development and manufacturing facilities as the region inte......
  • Global Pregnancy Detection Kit Market 2015-2019
    Published: 26-Nov-2014        Price: US $2500 Onwards        Pages: 78
    Pregnancy detection kits are diagnostic products that check for chemical markers related to pregnancy. These kits take up the midstream format, which is one of the three categories under rapid pregnancy tests. The remaining two are the strip format and the card or cassette format. A pregnancy detection kit uses rapid chromatographic immunoassay technique for the detection of hCG in urine to indicate pregnancy. Although these detection kits are available to both the OTC and professional markets, ......
  • Global Pulse Oximetry Market 2015-2019
    Published: 26-Nov-2014        Price: US $2500 Onwards        Pages: 66
    Pulse oximetry is a non-invasive method used to measure the arterial oxygen saturation level in patient's blood. Pulse oximetry works on the principle of spectrophotometry. The technique makes use of characteristics of hemoglobin for absorption of light and the pulsating nature of blood flow in the arteries. Using a pulse oximeter, hypoxia (a condition in which there is an inadequate oxygen supply in the body or a region of the body) can be detected before patients become cyanosed clinically. Pu......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs